Incyte Announces Positive Phase II Clinical Trial Results of Oral JAK1 Inhibitor in Patients with Active RA
Incyte Corporation (NASDAQ: INCY) announced results from a 12-week,
placebo-controlled, dose-escalation Phase II proof-of-concept clinical
trial involving 60 patients with active rheumatoid arthritis for its
proprietary oral JAK1 inhibitor. These results were presented today at
the 2013 American College of Rheumatology / Association of Rheumatology
Health Professionals (ACR/ARHP) Annual Scientific Meeting being held in
San Diego, CA, from Oct. 25 to 30, 2013.
“Along with our recently presented data with INCB39110 in psoriasis,
results from this study in rheumatoid arthritis demonstrate the
potential of JAK1 inhibition in inflammatory indications,” stated
Richard S. Levy, Incyte's Executive Vice President and Chief Drug
Development and Medical Officer.